Gilead Sciences announced that the European Commission has granted marketing authorization for Yeytuo (lenacapavir), the ...

The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV ...

While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an ...

We recently published Top 10 Trending Stocks to Watch Ahead of Nvidia Earnings. Gilead Sciences Inc (NASDAQ:GILD) is one of ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

Gilead Sciences won European approval Tuesday for its new twice-annual HIV prevention shot, now called Yeytuo.

Gilead Sciences’ twice-yearly injectable HIV-1 capsid inhibitor, Yeytuo receives European marketing authorization: Foster City, California Thursday, August 28, 2025, 12:00 Hrs [ ...

Investing.com -- Gilead Sciences (NASDAQ:GILD) said Tuesday it has received European Commission (EC) approval for its ...

Approved in June for people at high risk of HIV, Yeztugo was shown to be nearly 100% effective at preventing infection in ...

Gilead has become the latest pharma to strengthen its in-vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. | Gilead has become the latest ...

Kite Pharma will buy Interius BioTherapeutics for $350 million in cash to add an in vivo CAR‑T platform that creates T‑cell ...

Gilead Sciences (GILD) stock in focus as its twice-yearly HIV PrEP therapy lenacapavir, is approved in the EU as Yeytuo for HIV prevention. Read more here.